Phosphatidylinositol Glycan Anchor Biosynthesis Class U Protein in Breast Cancer
NCT ID: NCT07130162
Last Updated: 2025-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
96 participants
OBSERVATIONAL
2025-09-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Pregnancy Associated Plasma Protein A (PAPPA) as a Biomarker in Breast Cancer.
NCT06174571
Oncologic Safety of Sentinel Lymph Node Biopsy in Clinically Palpable Axillary Lymph Node in Breast Cancer Patients
NCT05703295
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
NCT04480814
Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants
NCT05054010
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer
NCT06169007
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* however even patients with similar prognostic features can experience different clinical outcomes after treatment . Despite significant advancements in early screening and diagnostic techniques, the incidence of breast cancer continues to rise annually, accounting for approximately 11.7% of all newly diagnosed cancer cases. So detection of new prognostic indicators is critical for selecting the optimal treatment modalities, evaluating the response and creating a follow-up plan to improve clinical outcome . Phosphatidylinositol glycan anchor biosynthesis class U (PIGU), also known as cell division cycle 91-like 1 (CDC91L1), is an important subunit of glycosylphosphatidylinositol transaminase (GPI-T) complex. It has been reported that the over-activity of certain components of the GPI T complex contributes to the development of various cancers, such as
breast cancer, bladder cancer, lymphoma, and non-small cell lung cancer. Studies have shown that PIGU has the potential to be a prognostic biomarker and therapeutic target for liver cancer, ovarian cancer and colorectal cancer . Also, PIGU expression levels have been associated with radiotherapy for differentiated thyroid cancer and the risk of cutaneous melanoma. It has been demonstrated that PIGU promotes hepatocellular carcinoma (HCC) progression via increasing HCC cell viability, migration, invasion and inhibiting apoptosis by activating the transcription factor nuclear factor-kappa B (NF-κB) pathway . Recent researches verify that PIGU protein levels were significantly higher in breast cancer patients compared to normal people
. So it was speculated that PIGU is playing an important role in tumor development, progression and it can be considered as a marker for breast cancer screening and prognosis (12).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
breast cancer patients
48 case
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
healthy controls
48 case
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who have already received chemotherapy or radiotherapy.
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esraa Gamal Neyaz Mohamed
Resident doctor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
An S, Liu F, Shi Y. Identification of serum phosphatidylinositol glycan anchor biosynthesis class U protein as diagnostic biomarker for breast cancer. Clin Chim Acta. 2025 Mar 1;569:120183. doi: 10.1016/j.cca.2025.120183. Epub 2025 Feb 6.
Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. doi: 10.3322/caac.21863. Epub 2024 Oct 1.
Azim HA, Elghazawy H, Ghazy RM, Abdelaziz AH, Abdelsalam M, Elzorkany A, Kassem L. Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis. JCO Glob Oncol. 2023 Mar;9:e2200387. doi: 10.1200/GO.22.00387.
Thakur N, Singh R, Sunigdha, Devgan R, Sharma A. Clinicopathological prognostic factors for survival in patients with breast cancer: a retrospective study from a tertiary cancer centre from North-West India. Ecancermedicalscience. 2025 Mar 6;19:1865. doi: 10.3332/ecancer.2025.1865. eCollection 2025.
Wei X, Yang W, Zhang F, Cheng F, Rao J, Lu L. PIGU promotes hepatocellular carcinoma progression through activating NF-kappaB pathway and increasing immune escape. Life Sci. 2020 Nov 1;260:118476. doi: 10.1016/j.lfs.2020.118476. Epub 2020 Sep 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PIGU in breast cancer
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.